Cancer drug developer Scancell Holdings PLC (LON:SCLP) presented the latest data from its Moditope platform at the International Cancer Immunotherapy conference in Germany – one of the most prestigious meetings in the industry’s calendar.
Moditope stimulates the production of killer CD4+ T cells that induce anti-tumour activity without toxicity.
The AIM-quoted firm’s chief scientific officer Lindy Durrant presented two posters at the conference on Friday.
The data showed that Modi-1 – the lead product from the platform – induced strong anti-tumour immunity in pancreatic, lung, ovarian and melanoma cancer models with up to 100% survival.
“Our poster in collaboration with ISA Pharmaceuticals showed that Modi-1 conjugated to synthetic TLR1/2 agonists generated an anti-tumour response at up to 100-fold lower doses than Modi-1 alone and that these conjugated peptides induced a memory response against tumour re-challenge,” said Durrant.
“These results suggest that Modi-1 conjugated directly to TLR agonists could be a powerful new approach to the treatment of cancer.”
Shares rose 0.9% to 14.12p.